Premier Fund Managers Ltd boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 8.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,240 shares of the company’s stock after buying an additional 6,255 shares during the quarter. Premier Fund Managers Ltd’s holdings in AbbVie were worth $8,131,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. CVA Family Office LLC purchased a new position in AbbVie in the third quarter worth $26,000. Harding Loevner LP grew its holdings in AbbVie by 118.4% in the third quarter. Harding Loevner LP now owns 332 shares of the company’s stock worth $29,000 after purchasing an additional 180 shares during the last quarter. Joseph P. Lucia & Associates LLC purchased a new position in AbbVie in the fourth quarter worth $29,000. James Investment Research Inc. purchased a new position in AbbVie in the third quarter worth $32,000. Finally, Roble Belko & Company Inc grew its holdings in AbbVie by 70.8% in the third quarter. Roble Belko & Company Inc now owns 415 shares of the company’s stock worth $36,000 after purchasing an additional 172 shares during the last quarter. 67.49% of the stock is currently owned by institutional investors.
In other news, EVP Timothy J. Richmond sold 51,990 shares of the business’s stock in a transaction dated Friday, November 27th. The shares were sold at an average price of $105.00, for a total transaction of $5,458,950.00. Following the completion of the sale, the executive vice president now owns 51,990 shares of the company’s stock, valued at $5,458,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Ryan Stewart sold 25,290 shares of the business’s stock in a transaction dated Tuesday, December 29th. The stock was sold at an average price of $105.00, for a total transaction of $2,655,450.00. Following the sale, the executive vice president now directly owns 76,259 shares of the company’s stock, valued at approximately $8,007,195. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.
ABBV has been the topic of several analyst reports. SVB Leerink lifted their price target on shares of AbbVie from $128.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, February 4th. Sanford C. Bernstein began coverage on shares of AbbVie in a research note on Tuesday, November 10th. They set an “outperform” rating and a $120.00 price objective for the company. BMO Capital Markets began coverage on shares of AbbVie in a research note on Wednesday, November 18th. They set an “outperform” rating and a $123.00 price objective for the company. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $114.00 price objective for the company in a research note on Tuesday, February 9th. Finally, Mizuho lifted their price objective on shares of AbbVie from $117.00 to $126.00 and gave the stock a “buy” rating in a research note on Thursday, February 4th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company’s stock. AbbVie presently has a consensus rating of “Buy” and an average price target of $114.39.
Shares of AbbVie stock traded down $0.11 during trading hours on Tuesday, reaching $106.95. The stock had a trading volume of 118,047 shares, compared to its average volume of 7,651,642. The stock’s 50 day moving average is $107.18 and its 200 day moving average is $97.93. The firm has a market capitalization of $188.82 billion, a PE ratio of 22.66, a PEG ratio of 1.54 and a beta of 0.84. AbbVie Inc. has a twelve month low of $62.55 and a twelve month high of $113.41. The company has a current ratio of 0.95, a quick ratio of 0.81 and a debt-to-equity ratio of 5.38.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Tuesday, February 2nd. The company reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.85 by $0.07. The business had revenue of $13.86 billion during the quarter, compared to the consensus estimate of $13.70 billion. AbbVie had a net margin of 18.16% and a return on equity of 439.24%. The company’s revenue was up 59.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.21 earnings per share. As a group, sell-side analysts predict that AbbVie Inc. will post 10.48 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, May 14th. Stockholders of record on Thursday, April 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, April 14th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 4.86%. AbbVie’s dividend payout ratio is currently 58.17%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More: What is a stock buyback?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.